ZW
Zwfis
Zwfis
Community Contributor
Member since 2025
Views20.1kTotal number of views
Followers272Total number of followers
Comments3Total number of comments

No bio added yet

No link added
PLX logo
Protalix BioTherapeutics

Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth

As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%.Read more

View narrative
283
users have viewed this narrative
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
US$4.23
29.8% undervalued intrinsic discount
Zwfis's Fair Value
Revenue
14% p.a.
Profit Margin
20%
Future PE
29.15x
Price in 2028
US$5.11
US$234.75
15.3% undervalued intrinsic discount
Zwfis's Fair Value
Revenue
13.6% p.a.
Profit Margin
10.54%
Future PE
31.96x
Price in 2028
US$295.73
US$228.21
34.0% overvalued intrinsic discount
Zwfis's Fair Value
Revenue
5.16% p.a.
Profit Margin
32.4%
Future PE
25x
Price in 2028
US$291.48
US$105.8
26.5% undervalued intrinsic discount
Zwfis's Fair Value
Revenue
13.23% p.a.
Profit Margin
23.24%
Future PE
20x
Price in 2028
US$136.72
US$152.71
46.6% undervalued intrinsic discount
Zwfis's Fair Value
Revenue
30.8% p.a.
Profit Margin
10%
Future PE
25x
Price in 2030
US$224.38
US$40.73
40.9% undervalued intrinsic discount
Zwfis's Fair Value
Revenue
6.22% p.a.
Profit Margin
11.11%
Future PE
10x
Price in 2028
US$51.3
US$37.42
22.9% undervalued intrinsic discount
Zwfis's Fair Value
Revenue
26.99% p.a.
Profit Margin
49%
Future PE
20x
Price in 2030
US$58.69